BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 32366840)

  • 1. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer.
    Wang G; Wang Q; Liang N; Xue H; Yang T; Chen X; Qiu Z; Zeng C; Sun T; Yuan W; Liu C; Chen Z; He X
    Cell Death Dis; 2020 May; 11(5):313. PubMed ID: 32366840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
    Wang C; Chen C; Hu W; Tao L; Chen J
    Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Microenvironment: Necroptosis Switches the Subtype of Liver Cancer While Necrosis Promotes Tumor Recurrence and Progression.
    Özdemir BH
    Exp Clin Transplant; 2023 Apr; 21(4):291-298. PubMed ID: 35297332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.
    Wang J; Dong M; Xu Z; Song X; Zhang S; Qiao Y; Che L; Gordan J; Hu K; Liu Y; Calvisi DF; Chen X
    Oncogene; 2018 Jun; 37(24):3229-3242. PubMed ID: 29545603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel murine model of combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Xu RC; Wang F; Sun JL; Abuduwaili W; Zhang GC; Liu ZY; Liu TT; Dong L; Shen XZ; Zhu JM
    J Transl Med; 2022 Dec; 20(1):579. PubMed ID: 36494846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.
    Ding N; Che L; Li XL; Liu Y; Jiang LJ; Fan B; Tao JY; Chen X; Ji JF
    World J Gastroenterol; 2016 Feb; 22(6):2071-80. PubMed ID: 26877611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Jiang S; Lu H; Pan Y; Yang A; Aikemu A; Li H; Hao R; Huang Q; Qi X; Tao Z; Wu Y; Quan C; Zhou G; Lu Y
    Cancer Lett; 2024 Apr; 588():216799. PubMed ID: 38479553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice.
    Liu Y; Xin B; Yamamoto M; Goto M; Ooshio T; Kamikokura Y; Tanaka H; Meng L; Okada Y; Mizukami Y; Nishikawa Y
    Cancer Sci; 2021 Aug; 112(8):3111-3124. PubMed ID: 34051011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.
    Gurzu S; Szodorai R; Jung I; Banias L
    J Cancer Res Clin Oncol; 2024 May; 150(5):270. PubMed ID: 38780656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype.
    Matter MS; Marquardt JU; Andersen JB; Quintavalle C; Korokhov N; Stauffer JK; Kaji K; Decaens T; Quagliata L; Elloumi F; Hoang T; Molinolo A; Conner EA; Weber A; Heikenwalder M; Factor VM; Thorgeirsson SS
    Hepatology; 2016 Jun; 63(6):1888-99. PubMed ID: 26844528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Necroptosis microenvironment directs lineage commitment in liver cancer.
    Seehawer M; Heinzmann F; D'Artista L; Harbig J; Roux PF; Hoenicke L; Dang H; Klotz S; Robinson L; Doré G; Rozenblum N; Kang TW; Chawla R; Buch T; Vucur M; Roth M; Zuber J; Luedde T; Sipos B; Longerich T; Heikenwälder M; Wang XW; Bischof O; Zender L
    Nature; 2018 Oct; 562(7725):69-75. PubMed ID: 30209397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
    Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
    Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
    Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling.
    Rosenberg N; Van Haele M; Lanton T; Brashi N; Bromberg Z; Adler H; Giladi H; Peled A; Goldenberg DS; Axelrod JH; Simerzin A; Chai C; Paldor M; Markezana A; Yaish D; Shemulian Z; Gross D; Barnoy S; Gefen M; Amran O; Claerhout S; Fernández-Vaquero M; García-Beccaria M; Heide D; Shoshkes-Carmel M; Schmidt Arras D; Elgavish S; Nevo Y; Benyamini H; Tirnitz-Parker JEE; Sanchez A; Herrera B; Safadi R; Kaestner KH; Rose-John S; Roskams T; Heikenwalder M; Galun E
    J Hepatol; 2022 Dec; 77(6):1631-1641. PubMed ID: 35988690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes.
    Xue R; Chen L; Zhang C; Fujita M; Li R; Yan SM; Ong CK; Liao X; Gao Q; Sasagawa S; Li Y; Wang J; Guo H; Huang QT; Zhong Q; Tan J; Qi L; Gong W; Hong Z; Li M; Zhao J; Peng T; Lu Y; Lim KHT; Boot A; Ono A; Chayama K; Zhang Z; Rozen SG; Teh BT; Wang XW; Nakagawa H; Zeng MS; Bai F; Zhang N
    Cancer Cell; 2019 Jun; 35(6):932-947.e8. PubMed ID: 31130341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma.
    Bai Y; Tong W; Xie F; Zhu L; Wu H; Shi R; Wang L; Yang L; Liu Z; Miao F; Zhao Q; Zhang Y
    Aging (Albany NY); 2021 Jul; 13(13):17592-17606. PubMed ID: 34237708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Look into hepatic progenitor cell associated trait: Histological heterogeneity of hepatitis B-related combined hepatocellular-cholangiocarcinoma.
    Cai X; Xiong J; Hu QG; Zhao QD; Wu D; Tang LG; Wan CD; Wei LX
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):873-879. PubMed ID: 29270746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics.
    Bergquist JR; Groeschl RT; Ivanics T; Shubert CR; Habermann EB; Kendrick ML; Farnell MB; Nagorney DM; Truty MJ; Smoot RL
    HPB (Oxford); 2016 Nov; 18(11):886-892. PubMed ID: 27546172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes.
    Sekiya S; Suzuki A
    J Clin Invest; 2012 Nov; 122(11):3914-8. PubMed ID: 23023701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.